These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6282216)

  • 41. [Basic and clinical studies of cefotiam in neonates and premature infants].
    Iwata S; Sato Y; Kusumoto Y; Shiro H; Akita H; Nanri S; Oikawa T; Osano M; Sunakawa K
    Jpn J Antibiot; 1986 Sep; 39(9):2407-20. PubMed ID: 3540358
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical effectiveness and pharmacokinetic characteristics of cefotaxime in premature infants with pneumonia].
    Parshina NV
    Antibiot Med Biotekhnol; 1986 Apr; 31(4):298-301. PubMed ID: 3717928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and safety of cefamandole in newborn infants.
    Agbayani MM; Khan AJ; Kemawikasit P; Rosenfeld W; Salazar D; Kumar K; Glass L; Evans HE
    Antimicrob Agents Chemother; 1979 May; 15(5):674-6. PubMed ID: 525985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.
    Regamey C
    Chemotherapy; 1985; 31(2):85-94. PubMed ID: 3987394
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A study of clinical application of cefotaxime in the perinatal period].
    Cho N; Fukunaga K; Kunii K
    Jpn J Antibiot; 1982 Jul; 35(7):1855-76. PubMed ID: 6294366
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefotaxime pharmacokinetics and treatment of meningitis in neonates.
    Jacobs RF; Kearns GL
    Infection; 1989; 17(5):338-42. PubMed ID: 2689352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and clinical evaluation of cefotaxime in children suffering with purulent meningitis.
    Bégué P; Floret D; Mallet E; Raynaud EJ; Safran C; Sarlangues J; Teyssier G
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():161-5. PubMed ID: 6094436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Basic and clinical studies on the use of cefotaxime in neonates].
    Toyonaga Y; Kurosu Y; Sugita M; Hori M
    Jpn J Antibiot; 1982 Jul; 35(7):1767-82. PubMed ID: 6294358
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients.
    Urien S; Laurent N; Barre J; Druguet M; Bouvier D'yvoire M; Maire P
    Eur J Clin Pharmacol; 2004 Mar; 60(1):11-6. PubMed ID: 14767629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cefotaxime: pharmacokinetics and in vitro antibacterial activity of serum and urine in normal human volunteers.
    Plouffe JF; Perkins RL; Fass RJ; Prior RB; Bernstein B; Ho I
    Chemotherapy; 1983; 29(2):73-9. PubMed ID: 6301775
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of cefotiam in humans.
    Rouan MC; Lecaillon JB; Guibert J; Modai J; Schoeller JP
    Antimicrob Agents Chemother; 1985 Feb; 27(2):177-80. PubMed ID: 3857018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative pharmacokinetics of four new cephalosporins: moxalactam, cefotaxime, cefoperazone and ceftazidime in neonates.
    Bégué P; Safran C; Quiniou F; Lasfargues G; Quinet B
    Dev Pharmacol Ther; 1984; 7 Suppl 1():105-8. PubMed ID: 6097425
    [No Abstract]   [Full Text] [Related]  

  • 53. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction.
    Wise R; Wright N
    Infection; 1985; 13 Suppl 1():S145-50. PubMed ID: 4055047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tobramycin sulfate elimination in premature infants.
    Arbeter AM; Saccar CL; Eisner S; Sarni E; Yaffe SJ
    J Pediatr; 1983 Jul; 103(1):131-5. PubMed ID: 6864378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion.
    Bertels RA; Semmekrot BA; Gerrits GP; Mouton JW
    Infection; 2008 Oct; 36(5):415-20. PubMed ID: 18791659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cefotaxime disposition pharmacokinetics during peritoneal dialysis.
    Overgaard S; Løkkegaard N; Scrøder S; Fugleberg S; Nielsen-Kudsk F
    Pharmacol Toxicol; 1987 May; 60(5):321-4. PubMed ID: 3615340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacokinetics and clinical evaluation of ceftizoxime (author's transl)].
    Shimizu S; Nobori T; Kawamura Y; Kamiya H; Sakurai M; Izawa T
    Jpn J Antibiot; 1982 Jan; 35(1):171-83. PubMed ID: 6279908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of cefotaxime in sheep.
    Guerrini VH; Filippich L; English PB; Bourne DW
    Am J Vet Res; 1983 Aug; 44(8):1488-91. PubMed ID: 6312852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.
    Ings RM; Fillastre JP; Godin M; Leroy A; Humbert G
    Rev Infect Dis; 1982; 4 Suppl():S379-91. PubMed ID: 6294787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.